List of works - Hiroki Ishihara

Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study

scientific article published on 06 September 2018

Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10-year, single center experience.

scientific article published on 8 August 2015

Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab

scientific article published on 29 March 2019

Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma

scientific article published on 19 December 2019

Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma

scientific article published on 16 March 2019

DNA methylation marker to estimate the breast cancer cell fraction in DNA samples

scientific article published on 14 September 2018

Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma

scientific article published on 01 July 2018

Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma

scientific article published on 01 September 2018

Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.

scientific article published on 14 June 2017

Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma

scientific article published on 01 December 2018

Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy.

scientific article published in February 2017

Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.

scientific article

Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: Case series of eight patients

scientific article published on 25 August 2019

Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.

scientific article

Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma

scientific article published on 01 May 2020

Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy

scientific article published on 01 June 2019

Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.

scientific article

Evaluation of Microvascular Inflammation in ABO-Incompatible Kidney Transplantation.

scientific article

Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study.

scientific article published on 20 April 2017

Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.

scientific article published on 23 April 2018

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

scientific article published on 13 November 2017

Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma.

scientific article published on 27 December 2016

Genetic and epigenetic profiling indicate the proximal tubule origin of renal cancers in end-stage renal disease

scientific article published on 29 August 2020

Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study

scientific article published on 01 October 2018

Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy

scientific article published on 25 September 2018

Late recurrence of a malignant hypoglycemia-inducing pelvic solitary fibrous tumor secreting high-molecular-weight insulin-like growth factor-II: A case report with protein analysis

scientific article

Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma

scientific article published on 01 November 2019

Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions

scientific article published on 21 May 2019

Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era?

scientific article published on 31 May 2020

Pancreatic Cancer Cell Fraction Estimation in a DNA Sample

scientific article published on 27 August 2018

Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan.

scientific article published on 7 March 2016

Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma

scientific article published on 01 August 2019

Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era

scientific article published on 04 March 2020

Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution

scientific article published on 11 February 2020

Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma

scientific article published on 18 December 2019

Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy.

scientific article published on 9 May 2017

Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Kidney Transplantation: A Multi-Institution Study in Japan Over 30 years.

scientific article published on 17 July 2017

Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma.

scientific article

Retroperitoneal catecholamine-producing ganglioneuroma with a birth history of monozygotic twins who both suffered from neuroblastoma during their childhoods: a case report with genome analysis

scientific article published on 30 July 2015

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers

scientific article published on 17 April 2019

Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment

scientific article published on 01 October 2016

Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study

scientific article published on 15 July 2016

The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma

scientific article published on 17 December 2019

The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma.

scientific article

Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.

scientific article published on 12 June 2017

Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma

scientific article published on 01 December 2019

List of works by Hiroki Ishihara

Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study

Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10-year, single center experience.

Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab

Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma

Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma

DNA methylation marker to estimate the breast cancer cell fraction in DNA samples

Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma

Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma

Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.

Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy.

Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.

Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: Case series of eight patients

Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.

Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma

Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy

Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.

Evaluation of Microvascular Inflammation in ABO-Incompatible Kidney Transplantation.

Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study.

Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma.

Genetic and epigenetic profiling indicate the proximal tubule origin of renal cancers in end-stage renal disease

Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study

Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy

Late recurrence of a malignant hypoglycemia-inducing pelvic solitary fibrous tumor secreting high-molecular-weight insulin-like growth factor-II: A case report with protein analysis

Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma

Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions

Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era?

Pancreatic Cancer Cell Fraction Estimation in a DNA Sample

Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan.

Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma

Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era

Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution

Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma

Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy.

Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Kidney Transplantation: A Multi-Institution Study in Japan Over 30 years.

Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma.

Retroperitoneal catecholamine-producing ganglioneuroma with a birth history of monozygotic twins who both suffered from neuroblastoma during their childhoods: a case report with genome analysis

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers

Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment

Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study

The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma

The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma.

Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.

Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma